GLP-1 drugs and surprise pregnancies: what the evidence shows

What did @realdrbae actually say?

The claim is that GLP-1 drugs like semaglutide are triggering unplanned pregnancies through two separate mechanisms. First, "delayed gastric emptying" reduces absorption of oral contraceptive pills, making them less effective. Second, people who were previously infertile due to obesity are now conceiving after losing weight, often without using contraception because they assumed they could not get pregnant. The video frames both as legitimate clinical concerns worth knowing before you start these medications.

To be clear: this is not pure scare content. The creator is a self-identified physician, the framing is educational rather than alarmist, and both mechanisms described are at least biologically plausible. That said, plausible is not the same as proven, and the video presents a fairly settled picture of something the evidence is still working out.

Does the science back this up?

Partially, yes. The gastric emptying mechanism is real, but how much it actually matters for oral contraceptive absorption is more complicated than the video lets on. The obesity-related infertility claim has stronger support.

On the pharmacokinetic side, semaglutide does slow gastric emptying, particularly in early treatment weeks. A 2023 study by Wium-Andersen et al. in BMJ Medicine flagged the drug interaction concern with oral medications broadly. However, a dedicated pharmacokinetic study of oral contraceptives with semaglutide, cited in the Ozempic prescribing information, found that while the timing of peak concentration (Tmax) shifted, overall exposure (AUC) was not significantly reduced. That distinction matters. The pill's effectiveness depends on overall absorption, not just peak timing.

On restored fertility through weight loss: there is solid evidence here. Polycystic ovary syndrome, which is heavily linked to obesity and insulin resistance, is one of the leading causes of anovulatory infertility. Studies including Legro et al. (2013, New England Journal of Medicine) showed weight loss significantly restored ovulation in women with PCOS. GLP-1 drugs appear to amplify this effect beyond weight loss alone, with emerging data suggesting direct ovarian effects.

What did they get wrong (or right)?

The obesity-infertility mechanism is the stronger half of this video, and the creator deserves credit for explaining it clearly. Many people genuinely do not know their infertility was weight-related rather than structural, and that is a real clinical gap.

The oral contraceptive absorption claim is where things get sloppy. The creator says "reduced absorption, less effectiveness" as if this is established fact. It is not. The pharmacokinetic data from semaglutide's own clinical trials showed a delay in absorption but no meaningful reduction in total drug exposure. The FDA-approved label for Ozempic notes this finding without recommending a backup method as a categorical requirement. Saying "you want to make sure you have a backup method" is not wrong as precautionary advice, but presenting it as a pharmacological certainty misrepresents what the studies actually show.

The term "delayed gastricymptin" appears to be a mangled version of "delayed gastric emptying," which is a minor presentation issue but worth noting given the video's reach.

What should you actually know?

If you are on a GLP-1 medication and using oral contraceptives, this is worth a real conversation with your prescriber, not a reason to panic. The data on absorption interference is genuinely mixed. Some clinicians do recommend a backup method during the first few weeks of GLP-1 treatment when gastric emptying effects are strongest, which is a reasonable precautionary position even if the pharmacokinetic data does not show a dramatic AUC reduction.

The restored fertility story is more important and more underappreciated. If you have been told you are infertile, or if you have PCOS, or if you stopped using contraception because you believed pregnancy was not possible, starting a GLP-1 drug may change that picture. This applies to weight-loss doses, not just diabetes-management doses. A 2024 analysis in Obesity by Joham and colleagues reinforced that GLP-1 agonists appear to improve reproductive hormonal profiles in women with obesity and PCOS independent of weight loss alone.

• Talk to your doctor before changing your contraception plan.
• If you have PCOS or obesity-related infertility, discuss your reproductive goals before starting treatment.
• Do not stop your current contraception without medical advice based on a TikTok video, including this one.

Bottom line

This video is better than most GLP-1 content circulating on social media. The core mechanisms are real. But the oral contraceptive claim is presented with more confidence than the evidence justifies, and 14 million viewers deserve that nuance. The fertility restoration story is the genuinely important public health message here, and it is the one that tends to get buried under the "Ozempic baby" headline framing.